![external](https://precision-biologics.com/wp-content/uploads/published-article-pdf.jpg)
Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy
Publication Date: 11/24/2023
![s13046-023-02649-6-pdf-226x300](https://precision-biologics.com/wp-content/uploads/s13046-023-02649-6-pdf-226x300-1.jpg)
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Publication Date: 3/29/2023
![download-screen-2022.12.06](https://precision-biologics.com/wp-content/uploads/download-screen-2022.12.06.png)
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
Publication Date: 10/12/2022
![download-screen-2022.07.21](https://precision-biologics.com/wp-content/uploads/download-screen-2022.07.21.png)
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas.
Cancers 2022, 14, 3037.
Publication Date: 6/21/2022
![download-screen-2020.08.25](https://precision-biologics.com/wp-content/uploads/download-screen-2020.08.25.png)
Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer
Publication Date: 8/25/2020
![download-screen-july15-2020](https://precision-biologics.com/wp-content/uploads/download-screen-july15-2020.png)
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer
Publication Date: 6/19/2020
![download-screen-NEO-102 Phase 2](https://precision-biologics.com/wp-content/uploads/download-screen-NEO-102-Phase-2-234x300.png)
Results of Precision Biologics Phase 2 Colorectal Cancer Study Published in Clinical Cancer Research
Publication Date: 4/17/2020
![download-screen-NEO-201](https://precision-biologics.com/wp-content/uploads/download-screen-NEO-201-234x300.png)
The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway
Publication Date: 1/2020
![download-screen-NEO-201](https://precision-biologics.com/wp-content/uploads/download-screen-NEO-201-234x300.png)
Rationale, discovery and clinical development of NEO-201
Publication Date: 11/2019
![An IL-15 Superagonists ALT-803](https://precision-biologics.com/wp-content/uploads/An-IL-15-Superagonists-ALT-803-234x300.png)
An IL-15 Superagonist, AL T-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
Publication Date: 3/2019
![Preclinical Characterization of Novel](https://precision-biologics.com/wp-content/uploads/Preclinical-Characterization-of-Novel-234x300.png)
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
Publication Date: 1/2018
![Neoantigens in the immuno-oncology space](https://precision-biologics.com/wp-content/uploads/Neoantigens-in-the-immuno-oncology-space-234x300.png)
Neoantigens in the immuno-oncology space
Publication Date: 10/2017
![A Phase 1 dose-escalation study NEO-102](https://precision-biologics.com/wp-content/uploads/A-Phase-1-dose-escalation-study-NEO-102-234x300.png)
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer
Publication Date: 7/2016
![Anti-tumor activity NPC-1C](https://precision-biologics.com/wp-content/uploads/Anti-tumor-activity-NPC-1C-234x300.png)
Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models
Publication Date: 3/2013